Nicotinamide Riboside Supplementation for Decreasing Inflammation in Middle-Aged and Older Adults

补充烟酰胺核苷可减少中老年人炎症

基本信息

批准号：
10461713
负责人：
Kaitlin Freeberg
金额：
$ 3.82万
依托单位：
UNIVERSITY OF COLORADO
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-08-01 至 2023-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10461713
关键词：
Adult Aftercare Age Anti-Inflammatory Agents Antiinflammatory Effect Aorta Arteries Biochemical Biochemistry Bioinformatics Biological Availability Biomedical Research Biometry Blood Pressure Blood specimen Caloric Restriction Cardiovascular Diseases Cardiovascular Physiology Carotid Arteries Cell Line Chronic Chronic Disease Chronic Kidney Failure Clinical Research Clinical Trials Collagen Colorado Deposition Development Development Plans Disease Double-Blind Method Elastin Elderly Environment Epidemic Event Functional disorder Funding Future Goals Health Human Hypertension Individual Inflammation Inflammatory Intervention Journals Laboratories Learning Leukocytes Link Lipopolysaccharides Measures Mediating Medical Mentors Metabolic Molecular Molecular Analysis Molecular Biology Mus Muscle Tonus NF-kappa B Nutraceutical Pathway interactions Peripheral Blood Mononuclear Cell Phase Physiologic pulse Physiological Physiology Pilot Projects Placebos Plasma Plasma Cells Population Process Production Public Health Randomized Research Research Personnel Research Priority Research Training Risk Risk Factors Role Safety Sampling Scientist Signal Pathway Stroke Structure Systems Biology Techniques Training Training Programs Translating Translational Research United States National Institutes of Health Universities Ursidae Family Vascular Smooth Muscle animal data arterial stiffness burden of illness capsule cardiovascular disorder risk cardiovascular health career development clinically relevant cytokine design disorder risk experience experimental study graduate student healthspan healthy lifestyle improved innovation insight metabolome metabolomics middle age mimetics nicotinamide riboside supplementation nicotinamide-beta-riboside novel novel marker oral supplementation parent grant pre-clinical seal skills symposium systemic inflammatory response targeted treatment transcription factor

项目摘要

CANDIDATE: Kaitlin A. Freeberg is a second-year graduate student in the Department of Integrative Physiology at the University of Colorado (CU) Boulder. Ms. Freeberg proposes to gain novel research training by taking advantage of opportunities provided by a recently initiated NIH R01-funded clinical trial of the nutraceutical compound, nicotinamide riboside (NR), for decreasing systolic blood pressure (SBP) and arterial stiffness in middle-aged and older adults with above-normal SBP. She seeks to perform additional experiments within this clinical trial by leveraging blood samples collected under the parent grant to determine the efficacy and mechanisms of action of NR for decreasing inflammation in this subject population. Her immediate goal is to gain the fundamental clinical and translational research experience and professional skills necessary to perform independent biomedical research. Her long-term goal is to become an academic scientist investigating creative strategies for improving cardiovascular (CV) function and health. CAREER DEVELOPMENT PLAN: Ms. Freeberg’s career development consists of: 1) gaining mentored experience conducting a randomized, placebo-controlled, double-blind, phase IIa clinical trial; 2) learning state-of-the-art biochemical and cellular techniques and molecular analyses to strengthen her translational research skills; 3) training in biostatistics and bioinformatics; 4) further developing her professional skills through formal coursework and participation in weekly laboratory journal clubs, university seminars, and national scientific conferences; and 5) interacting regularly with her mentoring team. ENVIRONMENT: Ms. Freeberg’s training plan environment is exceptional. The sponsor, Dr. Seals, has >30 years of NIH-funded research experience and a successful record of mentoring trainees in translational research to improve CV function in groups with increased CV disease (CVD) risk. Co- mentor Dr. You is a biostatistician at the CU Anschutz Medical Campus. Co-mentor Dr. Ziemba, who directs our biochemistry core research and training program, has extensive experience designing and performing innovative cellular and molecular translational research experiments. RESEARCH: Above-normal SBP and arterial stiffness increase CVD risk. Increases in SBP and arterial stiffness are mediated, in part, by chronic inflammation. NR supplementation is a promising healthspan- extending strategy to reduce inflammation, SBP and arterial stiffness in adults with above-normal SBP. This research will investigate the efficacy of NR treatment for reducing chronic inflammation (Aim 1) and identify treatment-induced changes in molecular signaling pathways via targeted plasma metabolomics analyses (Aim 2) that directly inhibit inflammatory cytokine production (Aim 3). Changes in these mechanistic processes will then be related to changes in SBP and arterial stiffness.

候选人：Kaitlin A. Freeberg是综合部门的二年级研究生科罗拉多大学（CU）Boulder的生理学。 Freeberg女士提议获得新的研究通过利用最近发起的NIH R01资助的临床培训营养素化合物，烟酰胺核苷（NR）的试验，以降低收缩压中年和老年人的（SBP）和动脉刚度高于正常的SBP。她寻求通过利用在此临床试验中进行其他实验父母的授予，以确定NR减少的效率和作用机理该受试者人群的炎症。她的直接目标是获得基本的临床和转化研究经验和专业技能才能独立执行生物医学研究。她的长期目标是成为研究创意的学术科学家改善心血管功能和健康的策略。职业发展计划： Freeberg女士的职业发展包括：1）获得进行重要的经验随机，安慰剂对照，双盲，IA期临床试验； 2）学习最新生化和细胞技术以及分子分析以加强她的翻译研究技能； 3）生物统计学和生物信息学的培训； 4）进一步发展她的专业技能通过正式的课程和参加每周实验室期刊俱乐部，大学中心，和国家科学会议； 5）定期与她的心理团队互动。环境：Freeberg女士的培训计划环境非常出色。赞助商海豹博士，拥有30年的NIH资助研究经验，并成功地记录了心理学员的记录转化研究以改善CV疾病（CVD）风险增加的组中的CV功能。共同导师博士您是Cu Anschutz医疗校园的生物统计学家。 Ziemba博士，他指导我们的生物化学核心研究和培训计划，具有丰富的经验设计和进行创新的细胞和分子翻译研究实验。研究：高于正常的SBP和动脉僵硬增加了CVD的风险。 SBP和动脉刚度的增加部分是由慢性炎症介导的。 NR补充是一个有前途的HealthSpan- 扩展策略以降低高度高正常的成年人的感染，SBP和动脉僵硬 SBP。这项研究将研究NR治疗减少慢性炎症的效率（AIM 1）并通过靶向等离子体确定治疗引起的分子信号通路变化代谢组学分析（AIM 2）直接抑制炎症性细胞因子产生（AIM 3）。然后，这些机械过程的变化将与SBP和动脉刚度的变化有关。